Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control
- 886 Downloads
Factor XIII (FXIII) is a transglutaminase consisting of two catalytic A subunits (FXIII-A) and two non-catalytic B subunits (FXIII-B) in plasma. FXIII-B protects FXIII-A from its clearance. FXIII-A is also present as a homodimer inside megakaryocytes/platelets and monocytes/macrophages. Although possible functions of intracellular FXIII-A have been proposed, these remain to be established. Intra- and extra-cellular FXIIIs support platelet adhesion and spreading as well as clot retraction, suggesting that FXIII is important for the stabilization of platelet–fibrin clots. Intra- and extra-cellular FXIIIs also support immobilization and killing of bacteria as well as phagocytosis by macrophages. Thus, FXIII may function in innate immunity. Congenital FXIII deficiency due to defective F13-A genes manifests as a life-long bleeding tendency, abnormal wound healing, and recurrent miscarriage. Although congenital FXIII-B deficiency used to be thought rare, reports of such cases have increased recently. As the bleeding tendency is often mild, patients with FXIII-B deficiency may be overlooked by physicians. Patients with acquired FXIII deficiency, in particular those with autoimmune hemorrhaphilia due to anti-FXIII antibodies, are on the increase, at least in Japan. It is important to diagnose such cases as early as possible, and to treat them with immunosuppression in combination with FXIII replacement therapy as their bleeding symptoms can be life-threatening.
KeywordsPlasma transglutaminase Fibrin-stabilizing factor Anti-fibrinolytic factor Innate immune factor Autoimmune hemorrhaphilia XIII/13 Hereditary factor XIII B subunit deficiency
We thank Dr. N. Hosono of Fukui Medical School, Prof. L. Muszbek of Debrecen University, Dr. V. Schroeder of Bern University, and Dr. M. Saito of Kanazawa University for communicating unpublished scientific or clinical data. This study was supported by a research grant from The Japanese Ministry of Health, Welfare, and Labor, and by a Grant-in-Aid for Scientific Research from Yamagata University, and was presented in part at the 23th ISTH meeting in Kyoto, Japan, in July 2011 and at the 73rd Annual Meeting of The Japanese Society of Hematology in Nagoya, Japan, in October 2011.
Conflict of interest
The author declares no conflict of interests.
- 4.Ivaskevicius V, Biswas A, Loreth R, Schroeder V, Ohlenforst S, Rott H, Krause M, Kohler HP, Scharrer I, Oldenburg J. Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia. 2010;16:675–82.PubMedGoogle Scholar
- 11.Rex S, Beaulieu LM, Perlman DH, Vitseva O, Blair PS, McComb ME, Costello CE, Freedman JE. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein–protein interactions, and alpha-granule release. Thromb Haemost. 2009;102:97–110.PubMedGoogle Scholar
- 12.Ohmori T, Yatomi Y, Asazuma N, Satoh K, Ozaki Y. Involvement of proline-rich tyrosine kinase 2 in platelet activation: tyrosine phosphorylation mostly dependent on alphaIIbbeta3 integrin and protein kinase C, translocation to the cytoskeleton and association with Shc through Grb2. Biochem J. 2000;347:561–9.PubMedCrossRefGoogle Scholar
- 14.Léon C, Eckly A, Hechler B, Aleil B, Freund M, Ravanat C, Jourdain M, Nonne C, Weber J, Tiedt R, Gratacap MP, Severin S, Cazenave JP, Lanza F, Skoda R, Gachet C. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood. 2007;110:3183–91.PubMedCrossRefGoogle Scholar
- 16.Takizawa H, Nishimura S, Takayama N, Oda A, Nishikii H, Morita Y, Kakinuma S, Yamazaki S, Okamura S, Tamura N, Goto S, Sawaguchi A, Manabe I, Takatsu K, Nakauchi H, Takaki S, Eto K. Lnk regulates integrin alphaIIbbeta3 outside-in signaling in mouse platelets, leading to stabilization of thrombus development in vivo. J Clin Invest. 2010;120:179–90.PubMedCrossRefGoogle Scholar
- 29.Brinkhous KM (1975) A short history of hemophilia, with some comments on the word “Hemophilia.” In: Brinkhous KM, Hemker HC (eds). Handbook of Hemophilia, Part 1, Amsterdam, New York: Excerpta Medica, American Elsevier Pub. Co.; 1975, pp 3–20Google Scholar
- 32.Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, for the UK Haemophilia Centre Doctors’ Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109:1870–7.PubMedCrossRefGoogle Scholar
- 36.Lorand L. Acquired inhibitors of fibrin stabilization: a class of hemorrhagic disorders of diverse origins. In: Green D, editor. Anticoagulants, physiologic, pathologic and pharmacologic. Boca Raton: CRC Press; 1994. p. 169–91.Google Scholar
- 37.Egbring R, Kröniger A, Seitz R. Erworbene Inhibitoren gegen Faktor XIII. Hämostaseologie. 1996;16:174–9.Google Scholar
- 49.Izumi T, Hashiguchi T, Castaman G, Tosetto A, Rodeghiero F, Girolami A, Ichinose A. Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. Blood. 1996;87:2769–74.PubMedGoogle Scholar
- 51.Capellato MG, Lazzaro AR, Marafioti F, Polato G, Girolami A. A new family with congenital factor XIII deficiency showing a deficit of both subunit A and B. Type I factor XIII deficiency. Haematologia (Budap). 1987;20:179–87.Google Scholar
- 52.Hashiguchi T, Saito M, Morishita E, Matsuda T, Ichinose A. Two genetic defects in a patient with complete deficiency of the b-subunit for coagulation factor XIII. Blood. 1993;82:145–50.Google Scholar
- 53.Souri M, Izumi T, Higashi Y, Girolami A, Ichinose A. A founder effect is proposed for factor XIII B subunit deficiency caused by the insertion of triplet AAC in exon III encoding the second Sushi domain. Thromb Haemost. 1998;80:211–3.Google Scholar
- 54.Alvarado LR, Lovejoy AE, Nakagawa P, Hsieh LB, Chediak J, Williams SA, Nugent DJ. A novel mutation in exon 10 of factor XIII subunit B. J Thromb Haemost. 2007;5(Suppl 2):P-T-043.Google Scholar